Evidence brief · printable

Schizophrenia evidence brief

One page, every section sourced. Print it or bring it on your phone.

Print or save as PDF Fits on one A4 or Letter page.

Schizophrenia: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 (capped at 1,000 of 1,859 matching trials) · https://research.opensourcemed.info/briefs/schizophrenia.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • Risperidone 6 trials
  • Aripiprazole 4 trials
  • Olanzapine 4 trials
  • Brexpiprazole (OPC-34712) 3 trials
  • Alpha Lipoic Acid 2 trials
  • Atomoxetine 2 trials

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Transcranial brain stimulation (tDCS, TMS) 108 trials · 37 completed · 18 with results
  • Cognitive training and remediation 46 trials · 21 completed · 10 with results
  • Cognitive behavioural and related therapies 43 trials · 23 completed · 4 with results
  • Psychotherapy, counselling and peer support 42 trials · 21 completed · 3 with results
  • Education, coaching and self-management 29 trials · 16 completed · 2 with results
  • Care coordination, navigation and outreach 8 trials · 4 completed · 2 with results

Natural products (RepurpOS Moderate tier)

Scale: RepurpOS evidence tier, from linked trials and literature. Product quality and dose vary.

  • N-Acetylcysteine
  • Vitamin B12
  • Glycine
  • Ashwagandha
  • L-Theanine
  • Chromium

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive… NCT07615426
  • Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia NCT04959201
  • Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia NCT04917302
  • Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium:… NCT07900893
  • Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization NCT07130500
  • Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive… NCT04296604

What we don't know yet

Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.

  • Mind-body and psychological approaches: cognition 17 trials, no results posted yet
  • Exercise and physical activity: physical function and exercise capacity 10 trials, no results posted yet
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (539 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.